New research from Dana-Farber Cancer Institute scientists suggests that cyclin-dependent kinase 2 (CDK2) inhibitors, which are currently being tested as treatments that slow the growth of a narrow ...

Mario Germano Giuliani and Lisa Giuliani have made an extraordinary gift of $27.8 million to support research in multiple myeloma, Dana-Farber Cancer Institute announced today. It is one of the ...

If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email media@dfci.harvard.edu.

Daraxonrasib is the first approved RAS-targeted therapy in pancreatic cancer Approval based primarily on Dana-Farber-led RASolute 302 trial showing daraxonrasib nearly doubled med ...

Take a video tour of Dana-Farber Cancer Institute - Chestnut Hill, a multi-disciplinary hospital facility located in the Chestnut Hill area of Newton, MA. It is available in English, Spanish, ...

The Dana-Farber Brigham Cancer Center Kidney Cancer team is composed of leaders in the field who are committed to providing you with the highest level of patient care. Our multidisciplinary team of ...

Grace Ho, MD is a Neuro-Oncologist at Dana-Farber Cancer Institute. She primarily treats patients with brain and spinal cord tumors including lymphoma, glioma, meningioma, ependymoma, schwannoma, ...

Dr. Molina graduated from Johns Hopkins University with a BS in Cellular and Molecular biology. He obtained his medical degree from Harvard Medical School and completed an MPH in Quantitative Methods ...

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab. This Phase 1, open-label study will ...

The primary objective of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD)/maximum tolerated combination dose (MTCD) or recommended phase 2 dose (RP2D) of AMG 994 as ...